Teva Announces Webcast on Results from Phase III ALLEGRO Study of Oral Laquinimod in Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) will host an audio webcast on
Thursday,  April 14 at 4:15 p.m. EDT  to present the results  from the Phase III
ALLEGRO   study   of   laquinimod,   an   investigational,   oral,   once-daily,
immunomodulator  for  the  treatment  of  relapsing remitting multiple sclerosis

For further information, please visit

Lund, April 11, 2011

Active Biotech AB (publ)

Tomas Leanderson
President & CEO

For further information, please contact:
Göran Forsberg
Vice President Investor Relations & Business Development
Tel +46 (0)46 19 11 54

Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit  for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was  provided  to  the  media  for  publication  on  April  11, 2011, at  08:30

Teva Announces Webcast on Results from Phase III ALLEGRO Study:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE